The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research and development will help the company to advance its innovative drugs, including cancer treatments. The Basel life sciences ecosystem is set to grow by another major global player. The international company Hengrui Medicine is establishing a Swiss subsidiary, Hengrui Europe Therapeutics AG. Founded in 1970, the Chinese company reportedly has a market capitalization of about USD 70 billion and therefore ranks as one of the top 30 life sciences companies in the world. It has more than 25,000 employees worldwide and currently runs more than 120 clinical trials globally. The Basel site will be dedicated to the clinical research and development of Hengrui’s innovative drugs in Europe. Hengrui Medicine operates in various fields, though its primary focus is on cancer treatments. The investment and innovation promotion agency Basel Area Business & Innovation is supporting Hengrui Medicine in establishing the Basel subsidiary.